Simone Sciabola

Simone Sciabola

Auto-generated profile, based on publicly available information

Simone Sciabola

Medicinal Chemistry, Biogen, Cambridge, Massachusetts 02142, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
CFCheng Fang
Cheng Fang
YWYe Wang
Ye Wang
RGRichard Grater
Richard Grater
SKSudarshan Kapadnis
Sudarshan Kapadnis
CBCheryl Black
Cheryl Black
SSSimone Sciabola
Simone Sciabola

30 May 2023 in Molecules
Verified
Journal Article
Open access
PDF file
YWYe Wang
Ye Wang
HZHonggang Zhao
Honggang Zhao
SSSimone Sciabola
Simone Sciabola
WWWenlu Wang
Wenlu Wang
Deep generative models applied to the generation of novel compounds in small-molecule drug design have attracted a lot of attention in recent years. To design compounds that interact with specific target proteins, we propose a Generative Pre-Trained Transformer (GPT)-inspired model for de novo target-specific molecular design. By implementing different keys and values for the multi-head attention conditional on a specified target, the proposed method can generate drug-like compounds both with and without a specific target. The results show that our approach (cMolGPT) is capable of generating SMILES strings that correspond to both drug-like and active compounds. Moreover, the compounds generated from the conditional model closely match the chemical space of real target-specific molecules and cover a significant portion of novel compounds. Thus, the proposed Conditional Generative Pre-Trained Transformer (cMolGPT) is a valuable tool for de novo molecule design and has the potential to accelerate the molecular optimization cycle time.

22 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSimone Sciabola
Simone Sciabola
HXHualin Xi
Hualin Xi
DCDario Cruz
Dario Cruz
QCQing Cao
Qing Cao
CLChristine Lawrence
Christine Lawrence
RSRobert Stanton
Robert Stanton
PFRED a software application for the design, analysis, and visualization of antisense oligonucleotides and siRNA is described. The software provides an intuitive user-interface for scientists to design a library of siRNA or antisense oligonucleotides that target a specific gene of interest. Moreover, the tool facilitates the incorporation of various design criteria that have been shown to be important for stability and potency. PFRED has been made available as an open-source project so the code can be easily modified to address the future needs of the oligonucleotide research community. A compiled version is available for downloading at https://github.com/pfred/pfred-gui/releases/tag/v1.0 as a java Jar file. The source code and the links for downloading the precompiled version can be found at https://github.com/pfred.

5 March 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
ZCZhonglin Cao
Zhonglin Cao
SSSimone Sciabola
Simone Sciabola
YWYe Wang
Ye Wang

7 May 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MHMartin K. Himmelbauer
Martin K. Himmelbauer
BBBekim Bajrami
Bekim Bajrami
RBRebecca Basile
Rebecca Basile
ACAndrew Capacci
Andrew Capacci
TCTeYu Chen
TeYu Chen
BHBrian T. Hopkins
Brian T. Hopkins
Multiple sclerosis (MS) is a chronic disease with an underlying pathology characterized by inflammation-driven neuronal loss, axonal injury, and demyelination. Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase and member of the TEC family of kinases, is involved in the regulation, migration, and functional activation of B cells and myeloid cells in the periphery and the central nervous system (CNS), cell types which are deemed central to the pathology contributing to disease progression in MS patients. Herein, we describe the discovery of BIIB129 (25), a structurally distinct and brain-penetrant targeted covalent inhibitor (TCI) of BTK with an unprecedented binding mode responsible for its high kinome selectivity. BIIB129 (25) demonstrated efficacy in disease-relevant preclinical in vivo models of B cell proliferation in the CNS, exhibits a favorable safety profile suitable for clinical development as an immunomodulating therapy for MS, and has a low projected total human daily dose.

2 March 2021 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
NPNandini C. Patel
Nandini C. Patel
BFBo Feng
Bo Feng
XHXinjun Hou
Xinjun Hou
MWMark A. West
Mark A. West
PTPatrick E. Trapa
Patrick E. Trapa
TWTravis T. Wager
Travis T. Wager